Licensing Opportunities

MDC innovations are available for exclusive or non-exclusive licensing across therapeutic domains. Select a compound, review its summary, and submit an interest form to initiate discussion.

Zn²⁺-Ivermectin (Antiviral)

Optimized for enhanced viral protein affinity and oral bioavailability. Preclinical insights support potential in respiratory and cytoplasmic-targeted viruses.

Submit Licensing Interest

Cu²⁺-Histidine (Neuroinflammation)

ROS-responsive agent with anti-inflammatory properties and metal-assisted delivery timing. Target: oxidative stress conditions in neurodegenerative pathways.

Submit Licensing Interest

Ru⁴⁺-Doxorubicin (Oncology)

Designed for selective tumor activation in acidic microenvironments. Enables logic-gated toxicity with metal-mediated stability.

Submit Licensing Interest

Bi³⁺-Minocycline (Spinal/CNS Repair)

MDC for neuroprotection, axonal regeneration, and trauma-targeted delivery. Currently under evaluation for spinal cord injury support.

Submit Licensing Interest
← Back to MDC Home/index